Form 4 for DRMA Dermata Therapeutics, Inc.
Accepted 2025-12-29 00:00:00 ET · period of report 2025-12-23 · accession 0001493152-25-029470 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-29 | 2025-12-23 | DRMA | Van Hoose Kyri K. | SVP, CFO | A - Grant | — | +122.5K | 130.4K | +1,556% | — |
| DM | 2025-12-29 | 2025-12-23 | DRMA | Van Hoose Kyri K. | SVP, CFO | A - Grant | — | +253.0K | 122.5K | New | — |
| D | 2025-12-29 | 2025-12-23 | DRMA | Van Hoose Kyri K. | SVP, CFO | D - Sale to Iss | — | +7,874 | 0 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-23 | A | A | 122,549 | — | 130,423 | D | — | — | (F2) The purchase price per share of common stock and accompanying warrants was $2.04. (F3) Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. |
| 2 | Derivative | Warrant (Right to Buy) | 2025-12-23 | A | A | 7,874 | — | 7,874 | D | $2.04 · — to — | 7,874 Common Stock | (F3) Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. (F6) In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act. |
| 3 | Derivative | Series C Warrant (Right to Buy) | 2025-12-23 | A | A | 122,549 | — | 122,549 | D | $2.04 · — to — | 122,549 Common Stock | (F2) The purchase price per share of common stock and accompanying warrants was $2.04. (F4) This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. |
| 4 | Derivative | Warrant (Right to Buy) | 2025-12-23 | D | A | 7,874 | — | 0 | D | $12.70 · — to — | 7,874 Common Stock | (F3) Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. (F6) In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act. |
| 5 | Derivative | Series D Warrant (Right to Buy) | 2025-12-23 | A | A | 122,549 | — | 122,549 | D | $2.04 · — to — | 122,549 Common Stock | (F2) The purchase price per share of common stock and accompanying warrants was $2.04. (F5) This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. |